Fibroin-derived protein composition
The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.
1. An ophthalmic formulation comprising water and a fibroin-derived protein composition, wherein:
the primary amino acid sequences of the fibroin-derived protein composition differ from native fibroin by at least 6% with respect to the combined amino acid content of serine, glycine, and alanine based on the combined absolute values of the differences in the content of serine, glycine, and alanine;
cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains of fibroin are reduced or eliminated;
a plurality of peptide chains in the protein composition terminate in amide (—C(═O)NH 2 ) groups;
the protein composition has a serine content that is reduced by greater than 40% compared to native fibroin protein;
the average molecular weight of the protein composition is less than about 60 kDa; and
the protein composition has an aqueous viscosity of less than 4 cP as a 10% w/w solution in water.
2. The ophthalmic formulation of claim 1 wherein the fibroin-derived protein composition comprises about 0.1% by weight to about 10% by weight of the ophthalmic formulation.
3. The ophthalmic formulation of claim 2 further comprising one or more of a buffering agent, a stabilizing agent, and a demulcent.
4. The ophthalmic formulation of claim 3 wherein the buffering agent or stabilizing agent comprises phosphate buffered saline, borate buffered saline, citrate buffer saline, sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium bicarbonate, zinc chloride, hydrochloric acid, sodium hydroxide, or edetate disodium.
5. The ophthalmic formulation of claim 3 wherein the demulcent comprises hyaluronic acid, hydroxyethyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, polyvinyl alcohol, polyethylene glycol, propylene glycol, dextran, gelatin, glycerin, polysorbate 80, or povidone.
6. The ophthalmic formulation of claim 3 further comprising one or more of a preservative, a vasoconstrictor, and an anti-histamine.
7. The ophthalmic formulation of claim 1 wherein the protein composition has an aqueous viscosity of less than 10 cP as a 24% w/w solution in water.
8. The ophthalmic formulation of claim 1 wherein the protein composition is soluble in water at 40% w/w without precipitation.
9. The ophthalmic formulation of claim 1 wherein the protein composition does not gel upon ultrasonication of an aqueous solution of the protein composition at concentrations of up to 10% w/w.
10. The ophthalmic formulation of claim 1 wherein the protein composition comprises less than 8% serine amino acid residues.
11. The ophthalmic formulation of claim 1 wherein the protein composition comprises greater than 46.5% glycine amino acids.
12. The ophthalmic formulation of claim 1 wherein the protein composition comprises greater than 30% alanine amino acids.
13. The ophthalmic formulation of claim 1 wherein the protein composition maintains an optical absorbance in aqueous solution of less than 0.25 at 550 nm after at least five seconds of ultrasonication.
14. The ophthalmic formulation of claim 1 wherein the average molecular weight of the fibroin-derived protein composition is about 35 kDa to about 45 kDa.